With higher Lp(a) levels typically seen in people of African and South Asian descent, Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, stresses the importance of including these populations in trials of novel Lp(a) lowering therapies so clinicians can be confident of their effects irrespective of patient ethnicity.
Please login or create a FREE account to view this content
Educational Partners of the 2nd Closed Scientific Expert Meeting of the Editorial Board
Principal partners:
Guest partners:
